Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanom...
Castle Biosciences, Inc. - Common stock (CSTL)
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Among all patients studied, 2.6% nodal positivity and 97.8% three-year recurrence-free survival (RFS) was observed in those predicted to have less than 5% risk of a positive sentinel lymph node (SLN) by DecisionDx-Melanoma’s i31-SLNB Only 1.4% SLN positivity was observed in patients with T1b–T2a tumors predicted to have less than 5% risk The Company will host a webcast on Monday, March 23, at 4:30pm Eastern Time to discuss data from the publication FRIENDSWOOD, Texas, March 13, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of results from the largest prospective, multicenter study to date evaluating DecisionDx-Melanoma’s integrated sentinel lymph node biopsy (i31-SLNB) test result.¹ The paper, available in Future Oncology, confirms that DecisionDx-Melanoma’s i31-SLNB identifies patients below the 5% National Comprehensive Cancer Network® (NCCN) threshol
Show less
Read more
Impact Snapshot
Event Time:
CSTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSTL alerts
High impacting Castle Biosciences, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CSTL
News
- Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript [Seeking Alpha]Seeking Alpha
- Castle Biosciences Highlights DECIDE Study: DecisionDx-Melanoma Refines SLNB and Recurrence Risk [Yahoo! Finance]Yahoo! Finance
- Why The Narrative Around Castle Biosciences (CSTL) Is Shifting With New Revenue Targets [Yahoo! Finance]Yahoo! Finance
- Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB [Yahoo! Finance]Yahoo! Finance
- SciBase: Interim report [Yahoo! Finance]Yahoo! Finance
CSTL
Earnings
- 2/26/26 - Beat
CSTL
Sec Filings
- 3/19/26 - Form 4
- 3/17/26 - Form 4
- 3/16/26 - Form 4
- CSTL's page on the SEC website